PAVM
(NASDAQ)
1.80
-0.0164  (-0.91%)
Volume (24h): 294.66K Day Range: 1.71 - 1.84
Market Cap: 68.61M 52W Range: 0.8101 - 3.45
Mar-24-20 01:30PM PAVmed to Hold Business Update Conference Call on April 9, 2020GlobeNewswire
Mar-09-20 01:30PM PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel DeviceGlobeNewswire
Mar-02-20 02:30PM PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) PatientsGlobeNewswire
Feb-20-20 02:30PM PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™GlobeNewswire
Feb-18-20 02:30PM PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product PipelineGlobeNewswire
Feb-12-20 02:18PM The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri DataBenzinga
Feb-11-20 02:30PM U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA TestGlobeNewswire
Jan-14-20 12:55PM The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid DrugBenzinga
Jan-13-20 02:30PM PAVmed Receives Formal Notification of Nasdaq Continued Listing ComplianceGlobeNewswire
Dec-19-19 02:30PM PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA TestGlobeNewswire
Dec-16-19 11:16PM Edited Transcript of PAVM earnings conference call or presentation 21-Nov-19 9:30pm GMTThomson Reuters StreetEvents
05:34PM Edited Transcript of PAVM earnings conference call or presentation 21-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Dec-13-19 02:30PM PAVmed Provides Update on CarpX™ Clinical Safety StudyGlobeNewswire
Nov-30-19 03:37AM Is PAVmed Inc. (PAVM) A Good Stock To Buy?Insider Monkey
Nov-29-19 04:13PM Edited Transcript of PAVM earnings conference call or presentation 21-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Nov-22-19 07:27AM Edited Transcript of PAVM earnings conference call or presentation 21-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Nov-21-19 09:00PM PAVmed Reports Third Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
Nov-14-19 02:30PM PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic ProductsGlobeNewswire
Nov-07-19 02:30PM PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple MilestonesGlobeNewswire
Nov-06-19 02:30PM PAVmed to Hold Business Update Conference Call on November 21, 2019GlobeNewswire
Nov-05-19 12:00PM PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to CommercializationGlobeNewswire
Sep-20-19 09:43AM Edited Transcript of PAVM earnings conference call or presentation 5-Sep-19 8:30pm GMTThomson Reuters StreetEvents
Sep-05-19 01:30PM PAVmed Reports Second Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
Aug-21-19 01:30PM USPTO Grants PAVmed Patent Covering its CarpX™ DeviceGlobeNewswire
Aug-15-19 01:30PM PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submissionGlobeNewswire
Aug-07-19 01:30PM PAVmed to Hold Business Update Conference Call on September 5, 2019GlobeNewswire
Jul-18-19 07:39PM What Kind Of Shareholder Appears On The PAVmed Inc.'s (NASDAQ:PAVM) Shareholder Register?Simply Wall St.
Jun-26-19 01:30PM PAVmed to Join Russell Microcap® IndexGlobeNewswire
Jun-24-19 02:46PM PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™GlobeNewswire
Jun-13-19 01:18PM Edited Transcript of PAVM earnings conference call or presentation 21-May-19 8:30pm GMTThomson Reuters StreetEvents
May-21-19 01:30PM PAVmed Reports First Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswire
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)